Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Bitton

Showing results (111-120 of 200) with videos related to

Pageof 20
Sort By:
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in CanadaKeeley L Rose, Philip M Sherman, Jane Cooke-Lauder, et al.
Immunology and Cell Biology|June 13, 2025
Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti-integrin therapyJohn D Rioux, Gabrielle Boucher, Anik Forest, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2024
A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel DiseaseJohn D Rioux, Gabrielle Boucher, Anik Forest, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services UtilizationM Ellen Kuenzig, Eric I Benchimol, Lawrence Lee, et al.
The Journal of Rheumatology|February 3, 2019
Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 3, 2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrinBrian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Journal of Cutaneous Medicine and Surgery|November 23, 2018
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive TherapiesKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Journal of the Canadian Association of Gastroenterology|October 17, 2019
Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD CareM Ellen Kuenzig, Lawrence Lee, Wael El-Matary, et al.
The Journal of Biological Chemistry|December 2, 2009
Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn diseaseTian-Tian Wang, Basel Dabbas, David Laperriere, et al.
Pageof 20

Showing results (111-120 of 200) with videos related to

Sort By:
Pageof 20
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in CanadaKeeley L Rose, Philip M Sherman, Jane Cooke-Lauder, et al.
Immunology and Cell Biology|June 13, 2025
Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti-integrin therapyJohn D Rioux, Gabrielle Boucher, Anik Forest, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2024
A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel DiseaseJohn D Rioux, Gabrielle Boucher, Anik Forest, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services UtilizationM Ellen Kuenzig, Eric I Benchimol, Lawrence Lee, et al.
The Journal of Rheumatology|February 3, 2019
Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 3, 2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrinBrian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Journal of Cutaneous Medicine and Surgery|November 23, 2018
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive TherapiesKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Journal of the Canadian Association of Gastroenterology|October 17, 2019
Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD CareM Ellen Kuenzig, Lawrence Lee, Wael El-Matary, et al.
The Journal of Biological Chemistry|December 2, 2009
Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn diseaseTian-Tian Wang, Basel Dabbas, David Laperriere, et al.
Pageof 20